

## **Supplementary methods**

### **BMD tests**

Lumbar spine (L1-L4) and femoral neck BMD ( $\text{g}/\text{cm}^2$ ) were measured using a dual energy X-ray absorptiometry (Discovery W; Hologic Inc., Waltham, MA, USA). The in vivo coefficient of variation of the measurements of 30 participants after repositioning was 1.02% and 1.18%, respectively, at the 2 bone sites. The long-term coefficient of variation was 0.26% by testing phantom calculations daily between March 2011 and May 2015. Osteoporosis was defined as a T-score of less than -2.5 and osteopenia was defined as a T-score between -2.5 and -1 based on a 30-year-old white female from the dual-energy X-ray absorptiometer manufacturer's reference database for the lumbar spine [1] and those of 20- to 29-year-old non-Hispanic white women from NHANES for the femoral neck [2].

### **Measurement of covariates**

The height and weight of the participants were measured to the nearest 0.1 cm and 0.1 kg, respectively, wearing light clothes and no shoes. Body mass index (BMI,  $\text{kg}/\text{m}^2$ ) was calculated. Sociodemographic factors, lifestyle and medical history information were collected through questionnaires in face-to-face interviews. Physical activities were assessed as total metabolic equivalent of daily task (MET) hours based on a validated physical activities questionnaire [3].

### **Collection and storage of stool and blood samples**

The stool samples were collected on-site at Sun Yat-sen University, temporarily stored in an ice box, manually stirred and then dispensed into a centrifuge tube and stored in

a refrigerator at -80°C within 4 hours. Immediately after collection, we checked that if the sample is adequate and the date of the collection have been recorded.

A twelve-hour fasting venous blood sample was collected from each participant. Serum was separated from blood within 2 hours. Before metabolomics analysis, all samples were stored at -80°C.

### **DNA extraction**

According to the manufacturer's instructions, the QIAamp® DNA Stool Mini Kit (Qiagen, Hilden, Germany) was used to extract microbial DNA from each sample. DNA concentration was determined using a Qubit quantitation system (Thermo Scientific, Wilmington, DE, US). The extracted DNA was stored at -20 °C.

### **16S gene amplicon sequencing**

The 16S rRNA gene amplification program was divided into two PCR steps. In the first PCR reaction, primers 341F (CCTACGGGNGGCWGCAG) and 805R (GACTACHVGGGTATCTAATCC) were used to amplify the V3-V4 hypervariable region of the 16S rRNA gene from genomic DNA [4]. Amplification was performed in a plate consisting of a 1X KAPA HiFi hot start premix, 0.1µM primer 341F, 0.1µM primer 805R and 12.5 ng template DNA with a total volume of 50 µL per sample. The reaction was carried out in a T100 PCR thermal cycle (BIO-RAD) according to the following cycle procedure: denaturation at 94 °C for 3 minutes, denaturation at 94 °C for 18 cycles, and change at 55 °C for 30 seconds, annealing at 55 °C for 30 seconds, elongation at 72 °C for 30 seconds and a final extension at 72 °C for 5 minutes. The amplification was examined by 2 % agarose gel electrophoresis and ethidium bromide

staining. Amplicons were quantified using a Qubit quantitation system (Thermo Scientific, Wilmington, DE, US) according to the manufacturer's instructions.

In the second PCR step, sequencing primers and adaptors were added to the amplicon product as follows: 2  $\mu$ L of the diluted amplicons were fused to a reaction solution consisting of 1 $\times$ KAPA HiFi Hotstart ReadyMix, 0.5  $\mu$ M fusion forward, 0.5  $\mu$ M fusion reverse primer, 30 ng Meta-gDNA (total volume 50  $\mu$ L). PCR was carried out according to the above cycle procedure except that the number of cycles was 12. The amplified product was purified using Agencourt AMPure XP Beads (Beckman Coulter Genomics, MA, USA) according to the manufacturer's instructions and quantified as described above. Equimolar amounts of amplification products were combined together in a single tube. The concentration of pooled libraries was determined by Qubit quantitation system. Amplicon sequencing was performed on an Illumina MiSeq system (Illumina Inc., CA, USA). MiSeq Reagent Kits v2 (Illumina Inc.) was used. Automated cluster generation and 2 $\times$ 250 bp paired end sequencing with double index reads were performed.

### **Bioinformatics—microbiome analysis**

The Fastq-files were demultiplexed by MiSeq Controller Software (Illumina Inc.). The sequences were trimmed for amplification of primers, diversity spacers and sequencing adaptors, merge-paired and quality filtered by USEARCH(v8.1) [5]. UPARSE [6] was used for OTU (operational taxonomic unit) clustering equal to or higher than 97%. The Ribosomal Database Project (RDP) classifier (v11.4) [7] was used for classification predictions to the lowest possible level. A representative

sequence for each OTU was selected to annotate the taxonomic information using the Greengenes reference database. The OTU data included 1356 OTUs, divided into 16 classes, 22 orders, 42 phyla, 41 families, 73 genera and 91 species. The OTUs were analyzed by the phylogenetic method in the Quantitative Insights into Microbial Ecology (QIIME v1.9.0) [8]. We calculated alpha diversity (Observed species, Chao1 index and Shannon index) based on the rarefied OTU counts.

We also used QIIME 2 2019.7 [9] to perform microbiome bioinformatics. We demultiplexed the raw sequence data and performed quality filtering using the q2-demux plugin (<https://github.com/qiime2/q2-demux>) and then denoised using DADA2[10] (via q2-dada2 [10]). All amplicon sequence variants (ASV) were aligned with MAFFT [11] (by q2-alignment (<https://github.com/qiime2/q2-alignment>)) and used to construct a phylogenetic tree with FastTree2 [12] (via q2-phylogeny (<https://github.com/qiime2/q2-phylogeny>)). ASVs were assigned to taxonomy using the q2-feature-classifier [13]. Silva 132 (16s/18s rRNA) reference database was used as reference data sets.

### **Microbial functional Analysis**

Metagenomic inference and functional analysis were performed through phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) [18] PICRUSt uses a computational method and used 16S data to predict a metagenome, thereby predicting which genes are present and predicting the functional composition of the metagenome.

### **Sample preparation and instrumentation for fecal metabolome**

Targeted metabolomics methods were used to analyze fecal samples and a total of 198 metabolites were quantified. The table S7 summarized the list of targeted fecal metabolites. The stool samples were melted on an ice bath to reduce degradation. Each sample was weighed approximately 10 mg and transferred to a new 1.5 mL test tube. Then the sample was added with 25  $\mu$ L of water and homogenized with the zirconia beads for 3 minutes. 185  $\mu$ L of acetonitrile / methanol (8/2) was added to extract metabolites. The sample was centrifuged at 18000g for 20 minutes. The supernatant was then transferred to 96-well plates. The following steps were performed on a Biomek 4000 workstation (Biomek 4000, Beckman Coulter, Inc., Brea, California, USA). 20  $\mu$ L of freshly prepared derivatization reagent was added to each well. The plate was sealed and derivatization was performed at 30 ° C for 60 minutes. After derivatization, 350  $\mu$ L of ice-cold 50% methanol solution was added to dilute the sample. The plate was then stored at -20 ° C for 20 minutes, and then centrifuged at 4000g for 30 minutes at 4 °C. 135  $\mu$ L of supernatant was transferred to a new 96-well plate, each containing 15  $\mu$ L of internal standard.

In this study, an ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) system (ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA, USA) was used to quantify microbial metabolites. The optimized instrument settings were briefly described below. ACQUITY UPLC BEH C18 1.7  $\mu$ M VanGuard pre-column (2.1  $\times$  5 mm) and ACQUITY UPLC BEH C18 1.7  $\mu$ M analytical column (2.1  $\times$  100 mm) were used. The column temperature was 40 ° C and the sample manager temperature was 10 ° C. Mobile phase A was water with 0.1% formic acid and

B is acetonitrile/IPA (90:10). The gradient conditions were as follows: 0-1 minutes (5% B), 1-12 minutes (5-80% B), 12-15 minutes (80-95% B), 15-16 minutes (95-100% B), 16-18 minutes (100% B), 18-18.1 minutes (100-5% B), 18.1-20 minutes (5% B), the flow rate was 0.40 mL/min. The capillary of the mass spectrometer was 1.5 (ESI +) and 2.0 (ESI -), while the ion source temperature and desolvation temperature were 150 °C and 550 °C, respectively. The desolvation gas flow was 1000 liters/hour.

### **Sample preparation and instrumentation for serum metabolome**

The table S8 summarized the list of targeted serum metabolites. The serum samples were thawed on ice bath to reduce sample degradation. 25 µL of serum was added to a 96-well plate. The plate was then transferred to a Biomek 4000 workstation (Biomek 4000, Beckman Coulter, Brea, California, USA). 100 µL of ice-cold methanol with part of the internal standard was automatically added to each sample and vortexed vigorously for 5 minutes. The plates were centrifuged at 4000 g for 30 minutes (Allegra X-15R, Beckman Coulter, Inc., Indianapolis, Indiana). Then the plate was put back into the workstation. 30 µL of the supernatant was transferred to a clean 96-well plate, and then 20 µL of the freshly prepared derivatization reagent was added to each well. The plate was sealed and derivatization was performed at 30°C for 60 minutes. After derivatization, 350 µL of ice-cold 50% methanol solution was added to dilute the sample. The plate was then stored at -20°C for 20 minutes and then centrifuged at 4000 g for 30 minutes at 4°C. 135 µL of supernatant was transferred to a new 96-well plate with each well containing 15 µL of internal standard. Serial dilutions of derivatized stock standards to the left well. Finally, the plate was sealed

for LC-MS analysis.

An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) system (ACQUITY UPLC-Xevo TQ-S, Waters Corporation, Milford, Massachusetts, USA) was used to quantify the microbial metabolites in the project. The optimized instrument settings are briefly introduced as follows. An ACQUITY UPLC BEH C18 1.7  $\mu$ M VanGuard pre-column (2.1  $\times$  5 mm) and an ACQUITY UPLC BEH C18 1.7  $\mu$ M analytical column were used. The column temperature was set at 40°C and the sample manager temperature was set at 10°C. The gradient started with 5% B (10% IPA in acetonitrile), maintained for 1 min, linearly increased to 80% B within 11 min, and increased to 95% B within 3 min, and then to 100% B at 16 min and maintained for 2 min. The flow rate through the column was 0.40 mL/min. The source temperature was set at 150°C. The desolvation gas flow was 1000 L/Hr.

### **Fecal and serum metabolome analytical quality control procedures**

The rapid conversion of many intracellular metabolites makes immediate metabolic quenching necessary. The extraction solvent was stored in a refrigerator at -20 ° C overnight and added to the sample immediately after thawing. An ice salt bath was used to keep the sample at a low temperature and minimize sample degradation during sample preparation. All prepared samples should be analyzed within 48 hours after sample extraction and derivatization.

Throughout the process of controlling each step from receiving samples in the laboratory to the final deliverables, a set of strict quality control/guarantee procedures were used to ensure consistent high-quality analysis results. The ultimate goal of

QA/QC was to provide reliable data for biomarker discovery research and/or assistance in molecular biology research. To this end, three types of quality control samples were commonly used on the metabolomics platform, namely test mixtures, internal standards and pooled biological samples. In addition to quality controls, conditioning samples and solvent blank samples were necessary to obtain the best instrument performance.

A test mixture containing a set of commercially available standards, whose mass range spans the mass range of the system, was used in the study sample. These samples were analyzed at the beginning and end of each batch run to ensure that the instrument operates within laboratory specifications (retention time stability, chromatographic peak shape, and peak signal intensity). The retention time offset should be within 4 seconds. The peak intensity difference of LC-MS should be within 15%.

The internal standard was added to the test sample to monitor the analysis changes throughout the sample preparation and analysis process. The combined QC samples were prepared by mixing aliquoted research samples so that the combined samples broadly represented the biological average of the entire sample set. The QC samples for this project were prepared together with the test samples and were injected regularly throughout the analysis run (after every 14 LC-MS test samples).

Reagent blank samples are solvent mixtures used for sample preparation and are usually processed using the same procedure as the sample to be analyzed. The reagent blank can be used as a useful alarm for system contamination. Because reagent blanks are composed of high-purity solvents and are analyzed in the same way as the study samples, they are also used to wash the chromatography column and remove



accumulated matrix effects throughout the study.

Calibrators include blank samples (matrix samples without internal standard treatment), zero samples (matrix samples treated with internal standard) and a series of seven concentrations, covering the expected range of metabolites present in a specific biological sample. LLOQ and ULOQ are the lowest and highest concentrations of the standard curve that can be measured with acceptable accuracy and precision. In order to reduce the analysis deviation in the entire analysis process, the samples were analyzed in pairs, but the random analysis was performed on each group. QC samples, calibrators and blank samples were analyzed throughout the entire sample set.

### **Software and quantification for fecal and serum metabolome**

The raw data files generated by UPLC-MS/MS were processed using QuanMET software (v2.0, Metabo-Proline, Shanghai, China) to perform peak integration, calibration, and quantification of each metabolite. The current QuanMET is hosted on a Dell PowerEdge R730 server running Linux Ubuntu 16.10 OS. The protected Java User Interface) allows users to access various statistical tools to view and browse project data according to their needs.

Quantitative metabolomics based on mass spectrometry refers to the determination of the concentration of a substance in an unknown sample by comparing the unknown sample with a set of standard samples with known concentrations (i.e., calibration curves). The calibration curve is a graph of how the analysis signal changes with the concentration of the analyte (substance to be measured). For most analyses, the plot of instrument response versus concentration will show a linear relationship. This will

produce a model described by the equation  $y = ax + b$ , where  $y$  is the instrument response, such as peak height or area,  $a$  represents slope/sensitivity, and  $b$  is a constant that describes the background. The analyte concentration ( $x$ ) of the unknown sample can be calculated according to this formula.

## **Statistical analysis**

### **Data imputation and representation**

Unless otherwise noted, statistical analyses were carried out in R environment (v3.4.0) and Stata (v14.0). BMD is as a classification (control, osteopenia and osteoporosis) metric. The data is expressed as the mean  $\pm$  SD or the indicated percentage. Metabolite variables with less than 50% missings were imputed using K-Nearest Neighbours (KNN).

### **Microbial feature differences among control, osteopenia and osteoporosis group**

LEfSe combines Kruskal-Wallis test or paired Wilcoxon rank sum test with linear discriminant analysis (LDA) [14]. LEfSe analysis was performed in two essential situations: the logarithmic LDA score threshold for the discriminant feature was equal to 2.0 [15], and the significance level was 0.05. We also calculated the mean and median of the biomarker relative abundance in each group.

### **Microbial function differences**

Output data from PICRUST were filtered for pathways which are significantly relevant for osteoporosis-related genera with multivariate linear regression by adjusting Bristol stool scale [17], sequencing run and sequencing depth. The  $p$  value was adjusted using the Benjamini-Hochberg false discovery rate (FDR) method. Relative abundance of

pathways from participants at each group (control, osteopenia and osteoporosis) were compared by LEfSe.

### **Correlation between osteoporosis-related genera and metabolite biomarkers**


Spearman correlation was used to test the association between microbial biomarkers (*Streptophyta Other*, *Phascolarctobacterium*, *Actinobacillus*, *Blautia*, *Oscillospira*, *Eggerthella*, *Rikenellaceae Other*, *Phascolarctobacterium*, *Bacteroides*, *Ruminococcaceae Other*, *Collinsella* and *Veillonellaceae Other*) with osteoporosis-related metabolites (fecal tyrosine and tryptophan, serum valine and leucine). Multiple tests were adjusted using the Benjamini and Hochberg method. FDR < 0.05 was considered statistically significant.

### **The definition of the microbe score**

To assess the association of the gut microbiota on metabolite pathways, we calculated the microbe score [16] for each individual based on the metabolite biomarker related-microbiota selected by the spearman method. For each individual sample, the score of sample  $j$ , represented by  $I_j$ , is calculated by the following formula:


$$I_j^n = \sum_{i \in N} A_{ij}$$
$$I_j^m = \sum_{i \in M} A_{ij}$$
$$I_j = (I_j^n - I_j^m) \times 100$$

Where  $A_{ij}$  is the relative abundance of marker  $i$  in sample  $j$ .  $N$  is all osteoporosis or osteopenia-enriched marker.  $M$  is all control-enriched markers.




**Figure S1.**  $\alpha$  diversity estimator, measured using the 16S rRNA gene OTUs. A and B, Shannon index within subjects by lumbar spine and femoral neck status. C and D, Observed species within subjects by lumbar spine and femoral neck status. E and F, Chao1 within subjects by lumbar spine and femoral neck status.

Femoral neck status



Lumbar spine status



**Figure S2.** Genus biomarkers relative abundance barplot from LEfSe. The solid line is the average value of relative abundance and the dotted line is the median value of relative abundance. (A, B, C, D, E, F, G, H, I and J) *Actinobacillus*, *Bacteriodes*, *Blautia*, *Eggerthella*, *Oscillospira*, *Rikenellaceae other*, *Collinsella*, *Ruminococcaceae other*, *Veillonellaceae other* and *Phascolarctobacterium* relative abundance barplot at femoral neck control, osteopenia and osteoporosis groups. (K and L) *Streptophyta other* and *Phascolarctobacterium* relative abundance barplot at lumbar spine control, osteopenia and osteoporosis groups.

Table S1. Characteristics of participants in the cross-sectional study for lumbar spine status (n = 1774) \*.

Variables	Lumbar spine status			p-value
	Control	Osteopenia	Osteoporosis	
n	1013	582	179	
Age, mean (SD)	64.6 (5.9)	64.7 (5.7)	64.5 (6.0)	0.855
Sex, n (%)				<b>&lt;0.001</b>
Female	565 (55.8)	471 (80.9)	158 (88.3)	
Male	448 (44.2)	213 (19.1)	21 (11.7)	
BMI, median (IQR)	23.4 (21.6,25.6)	23.1 (21.2,25.1)	23.6 (21.6,25.3)	0.070
Education, n (%)				0.176
Junior high school and below	280 (27.6)	145 (24.9)	56 (31.3)	
High school or secondary school	458 (45.2)	284 (48.8)	69 (38.5)	
College and above	275 (27.1)	153 (26.3)	54 (30.2)	
Physical activities quartile, n ()				0.256
Q1	255 (25.2)	139 (23.9)	50 (27.9)	
Q2	267 (26.4)	136 (23.4)	41 (22.9)	
Q3	232 (22.9)	163 (28.0)	49 (27.4)	
Q4	259 (25.6)	144 (24.7)	39 (21.8)	
BMD, median (IQR)	1.08 (1.01,1.20)	0.86 (0.83,0.90)	0.73 (0.69,0.75)	<b>&lt;0.001</b>

\*Difference in population characteristics among participants as normal control, osteopenia or osteoporosis was examined by analysis of covariance (continuous variables in normal distribution) or Kruskal-Wallis (continuous variables in non-normal distribution) or chi-square test (categorical variables).

Table S2. Characteristics of participants in the cross sectional-study for femoral neck status (n = 1776) \*.

Variables	Femoral neck status			p-value
	Control	Osteopenia	Osteoporosis	
n	483	1027	266	
Age, median (IQR)	64.1 (61.2,68.5)	64.0 (60.5,68.3)	65.2 (61.4,69.3)	<b>0.041</b>
Sex, n (%)				<b>&lt;0.001</b>
Female	194 (40.2)	759 (73.9)	243 (91.4)	
Male	289 (59.8)	268 (46.2)	23 (8.6)	
BMI, median (IQR)	23.4 (21.5,25.8)	23.3 (21.4,25.3)	23.1 (21.3,25.2)	0.230
Education, n (%)				<b>0.013</b>
Junior high school and below	146 (30.2)	264 (25.7)	72 (27.1)	
High school or secondary school	202 (41.8)	503 (49.0)	107 (40.2)	
College and above	135 (28.0)	260 (25.3)	87 (32.7)	
Physical activities quartile, n ()				0.10
Q1	133 (27.5)	237 (23.1)	74 (27.8)	
Q2	129 (26.7)	263 (25.6)	52 (19.5)	
Q3	114 (23.6)	258 (25.1)	72 (27.1)	
Q4	107 (22.2)	269 (26.2)	68 (25.6)	
BMD, median (IQR)	0.80 (0.77,0.86)	0.65 (0.60,0.69)	0.53 (0.50,0.54)	<b>&lt;0.001</b>

\*Difference in population characteristics among participants as normal control, osteopenia or osteoporosis was examined by analysis of covariance (continuous variables in normal distribution) or Kruskal-Wallis (continuous variables in non-normal distribution) or chi-square test (categorical variables).

Table S3. Variance of OTU profiles explained by lumbar spine osteoporosis and covariates in the cross-sectional adonis analysis (n = 1774).

	R <sup>2</sup>	<i>p</i> value
Lumbar spine osteoporosis	0.0014	0.082
Age	0.0003	0.982
Sex	0.0008	0.068
Physical activity	0.0006	0.360
Sequencing run	0.0009	<b>0.049</b>
Bristol scale	0.0004	0.792

Table S4. Variance of OTU profiles explained by femoral neck osteoporosis and covariates in the cross-sectional adonis analysis (n = 1776).

	R <sup>2</sup>	<i>p</i> value
Femoral neck osteoporosis	0.0022	<b>0.001</b>
Age	0.0006	0.250
Sex	0.0021	<b>0.001</b>
Physical activity	0.0005	0.425
Sequencing run	0.0410	<b>0.001</b>
Bristol scale	0.0189	<b>0.001</b>



Table S5. Variance of taxonomic profiles explained by different status of lumbar spine in the cross-sectional adonis analysis (n = 1774).

	R <sup>2</sup>	<i>p</i> value
Lumbar spine status*	0.0009	<b>0.078</b>
Normal		
Abnormal (osteopenia/osteoporosis)		
Lumbar spine status <sup>†</sup>	0.0009	<b>0.026</b>
Normal		
Abnormal (osteopenia/osteoporosis)		
Lumbar spine status <sup>‡</sup>	0.0015	<b>0.131</b>
Normal		
Osteopenia		
Osteoporosis		
Lumbar spine status <sup>§</sup>	0.0015	<b>0.061</b>
Normal		
Osteopenia		
Osteoporosis		

\*Variance of genus profiles by QIIME v1.9.0 explained by lumbar spine status.

<sup>†</sup>Variance of OTU profiles by QIIME v1.9.0 explained by lumbar spine status.

<sup>‡</sup>Variance of genus profiles by QIIME 2 2019.4 explained by lumbar spine status.

<sup>§</sup>Variance of ASV profiles by QIIME 2 2019.4 explained by lumbar spine status.

Table S6. Variance of taxonomic profiles explained by different status of femoral neck in the cross-sectional adonis analysis (n = 1776).

	R <sup>2</sup>	<i>p</i> value
Femoral neck status <sup>*</sup>	0.0015	<b>0.004</b>
Normal		
Abnormal (osteopenia/osteoporosis)		
Femoral neck status <sup>†</sup>	0.0014	<b>0.001</b>
Normal		
Abnormal (osteopenia/osteoporosis)		
Femoral neck status <sup>‡</sup>	0.0020	<b>0.011</b>
Normal		
Osteopenia		
Osteoporosis		
Femoral neck status <sup>§</sup>	0.0019	<b>0.002</b>
Normal		
Osteopenia		
Osteoporosis		

<sup>\*</sup>Variance of genus profiles by QIIME v1.9.0 explained by femoral neck status.

<sup>†</sup>Variance of OTU profiles by QIIME v1.9.0 explained by femoral neck status.

<sup>‡</sup>Variance of genus profiles by QIIME 2 2019.4 explained by femoral neck status.

<sup>§</sup>Variance of ASV profiles by QIIME 2 2019.4 explained by femoral neck status.

## References

- 1 Looker AC, Melton LJR, Borrud LG, Shepherd JA. Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status. *Osteoporos Int* 2012;**23**:1351-60.
- 2 Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJR, Khaltaev N. A reference standard for the description of osteoporosis. *Bone* 2008;**42**:467-75.
- 3 Liu B, Woo J, Tang N, Ng K, Ip R, Yu A. Assessment of total energy expenditure in a Chinese population by a physical activity questionnaire: examination of validity. *Int J Food Sci Nutr* 2001;**52**:269-82.
- 4 Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, *et al.* Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. *Nucleic Acids Res* 2013;**41**:e1.
- 5 Edgar RC. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* 2010;**26**:2460-1.
- 6 Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. *Nature Methods* 2013;**10**:996.
- 7 Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, *et al.* Ribosomal Database Project: data and tools for high throughput rRNA analysis. *Nucleic Acids Res* 2014;**42**:D633-42.
- 8 Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, *et al.* QIIME allows analysis of high-throughput community sequencing data. *Nature methods* 2010;**7**:335-6.
- 9 Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, *et al.* Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol* 2019;**37**:852-7.
- 10 Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. *Nature Methods* 2016;**13**:581.
- 11 Katoh K, Misawa K, Kuma K-i, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic acids research* 2002;**30**:3059-66.
- 12 Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. *PLoS one* 2010;**5**:e9490-e.
- 13 Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, *et al.* Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. *Microbiome* 2018;**6**:90-.
- 14 Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, *et al.* Metagenomic biomarker discovery and explanation. *Genome Biol* 2011;**12**:R60.
- 15 Szafranski SP, Wos-Oxley ML, Vilchez-Vargas R, Jauregui R, Plumeier I, Klawonn F, *et al.* High-resolution taxonomic profiling of the subgingival microbiome for biomarker discovery and periodontitis diagnosis. *Appl Environ Microbiol* 2015;**81**:1047-58.
- 16 Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, *et al.* A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* 2012;**490**:55-60.
- 17 Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. *Scand J Gastroenterol* 1997;**32**:920-4.
- 18 Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, *et al.* Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* 2013;**31**:814-21.

